Thomas J. Cahill, MD, PhD, is the founder and Managing Director of Newpath Partners LLC, where he focuses on uniquely aligning interests between academics, investors, and management. Prior to Newpath, he worked at the Raptor Group where he helped further establish and lead the life-science/healthcare and technology investment portfolio.
Dr. Cahill’s research experience has spanned from the basic sciences to the pharmaceutical landscape, and he recently started a company, Molindra Therapeutics, focused on discovering drugs for a new class of receptor target. His work has led to numerous peer-reviewed publications and awards.
Dr. Cahill received both his MD and PhD from Duke University. His PhD work with Nobel Laureate Robert Lefkowitz focused on the biophysical and structural properties of cellular receptors and their signaling to inform novel drug development and discovery.
Dr. Cahill obtained an MS in Chemistry from Stanford University focused on reaction dynamics and drug delivery in the laboratory of Professor Richard Zare. As an undergraduate, Dr. Cahill’s research at Cornell University with Nobel Laureate Roald Hoffmann focused on theoretical and computational chemistry.
Back to Our Team